Patents Assigned to BicycleTx Limited
-
Patent number: 11970555Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which bind to TfR1. The invention also relates to multimeric binding complexes which comprise at least two of said bicyclic peptide ligands. The invention also includes pharmaceutical compositions comprising said peptide ligands and multimeric binding complexes and the use of said peptide ligands, and multimeric binding complexes and pharmaceutical compositions in preventing, suppressing or treating a disease or disorder through TfR1 mediated delivery of a therapeutic agent.Type: GrantFiled: November 12, 2021Date of Patent: April 30, 2024Assignee: BicycleTx LimitedInventors: Ellen Gowans, Gemma Elizabeth Mudd, Michael Rigby, Punit Seth, Michael Skynner, Steven Stanway, Liudvikas Urbonas, Katerine Van Rietschoten
-
Patent number: 11970553Abstract: The present invention relates to a heterotandem bicyclic peptide complex which comprises a first peptide ligand, which binds to Nectin-4, conjugated via a linker to two second peptide ligands, which bind to CD137. The invention also relates to the use of said heterotandem bicyclic peptide complex in preventing, suppressing or treating cancer.Type: GrantFiled: February 4, 2022Date of Patent: April 30, 2024Assignee: BicycleTx LimitedInventors: Gemma Mudd, Punit Upadhyaya, Kevin McDonnell, Johanna Lahdenranta
-
Patent number: 11912792Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.Type: GrantFiled: August 17, 2022Date of Patent: February 27, 2024Assignee: BicycleTx LimitedInventors: Paul Beswick, Liuhong Chen, Gemma Mudd, Peter Park, Katerine Van Rietschoten, Michael Rigby
-
Patent number: 11904020Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which bind to TREM2. The invention also relates to multimeric binding complexes which comprise at least two of said bicyclic peptide ligands. The invention also includes pharmaceutical compositions comprising said peptide ligands and multimeric binding complexes and the use of said peptide ligands, multimeric binding complexes and pharmaceutical compositions in preventing, suppressing or treating a disease or disorder mediated by TREM2.Type: GrantFiled: March 18, 2022Date of Patent: February 20, 2024Assignee: BicycleTx LimitedInventors: Paul Brennan, Amy Brown, Liuhong Chen, John Davis, Yuliya Demydchuk, Donatella Di Rienzo, Ellen Gowans, Rama McCrory, Emma Mead, Emma Murphy, Mike Rigby, Michael Skynner, Tom Smith, Steven Stanway
-
Patent number: 11866518Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of thymic stromal lymphopoietin (TSLP). The invention also includes pharmaceutical compositions comprising said peptide ligands and to the use of said peptide ligands in preventing, suppressing or treating a disease or disorder mediated by TSLP.Type: GrantFiled: April 6, 2021Date of Patent: January 9, 2024Assignee: BicycleTx LimitedInventors: Frank Narjes, Tor Svensson, Pavol Zlatoidsky, Lotta Hidestal, Liuhong Chen, Michael Skynner, Sophie Watcham
-
Patent number: 11833211Abstract: The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of the Eph receptor tyrosine kinase A2 (EphA2). The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder characterised by overexpression of EphA2 in diseased tissue (such as a tumour).Type: GrantFiled: September 23, 2022Date of Patent: December 5, 2023Assignee: BicycleTx LimitedInventors: Liuhong Chen, Philip Huxley, Silvia Pavan, Katerine Van Rietschoten
-
Patent number: 11730819Abstract: A compound comprising at least one looped peptide structure attached via at least one alkylamino linkage to a scaffold. Preferably the looped peptide structure is a Bicycle structure comprising two peptide loops attached to the scaffold via two alkylamino linkages and one thioether linkage, one of the linkages being common to both loops.Type: GrantFiled: December 20, 2017Date of Patent: August 22, 2023Assignee: BicycleTx LimitedInventors: Daniel Teufel, Gemma Mudd, Silvia Pavan
-
Patent number: 11696956Abstract: The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of the Eph receptor tyrosine kinase A2 (EphA2). The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder characterised by overexpression of EphA2 in diseased tissue (such as a tumour).Type: GrantFiled: December 19, 2018Date of Patent: July 11, 2023Assignee: BicycleTx LimitedInventors: Liuhong Chen, Philip Huxley, Silvia Pavan, Katerine Van Rietschoten
-
Patent number: 11613560Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which bind to OX40. The invention also relates to multimeric binding complexes of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold that are functional agonists of OX40. The invention also includes drug conjugates comprising said peptides and complexes, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands, complexes and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by OX40.Type: GrantFiled: May 11, 2020Date of Patent: March 28, 2023Assignee: BicycleTx LimitedInventors: Tom Li Stephen, Kevin McDonnell, Nicholas Keen, Liuhong Chen, Helen Harrison, Peter U. Park, Michael Skynner, Harvey Che
-
Patent number: 11484602Abstract: The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of the Eph receptor tyrosine kinase A2 (EphA2). The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder characterised by overexpression of EphA2 in diseased tissue (such as a tumour).Type: GrantFiled: December 14, 2018Date of Patent: November 1, 2022Assignee: BicycleTx LimitedInventors: Liuhong Chen, Philip Huxley, Silvia Pavan, Katerine Van Rietschoten
-
Patent number: 11453703Abstract: The present invention relates to heterotandem bicyclic peptide complexes which comprise a first peptide ligand, which binds to a component present on an immune cell, conjugated via a linker to a second peptide ligand, which binds to a component present on a cancer cell. The invention also relates to the use of said heterotandem bicyclic peptide complexes in preventing, suppressing or treating cancer.Type: GrantFiled: April 2, 2019Date of Patent: September 27, 2022Assignee: BICYCLETX LIMITEDInventors: Nicholas Keen, Kevin McDonnell, Peter Park, Punit Upadhyaya, Gemma Mudd
-
Patent number: 11453702Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.Type: GrantFiled: September 30, 2021Date of Patent: September 27, 2022Assignee: BICYCLETX LIMITEDInventors: Paul Beswick, Liuhong Chen, Gemma Mudd, Peter Park, Katerine Van Rietschoten, Michael Rigby
-
Publication number: 20220296726Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which bind to TREM2. The invention also relates to multimeric binding complexes which comprise at least two of said bicyclic peptide ligands. The invention also includes pharmaceutical compositions comprising said peptide ligands and multimeric binding complexes and the use of said peptide ligands, multimeric binding complexes and pharmaceutical compositions in preventing, suppressing or treating a disease or disorder mediated by TREM2.Type: ApplicationFiled: March 18, 2022Publication date: September 22, 2022Applicant: BicycleTx LimitedInventors: Paul Brennan, Amy Brown, Liuhong Chen, John Davis, Yuliya Demydchuk, Donatella Di Rienzo, Ellen Gowans, Rama McCrory, Emma Mead, Emma Murphy, Mike Rigby, Michael Skynner, Tom Smith, Steven Stanway
-
Publication number: 20220257784Abstract: The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of the Eph receptor tyrosine kinase A2 (EphA2). The invention also relates to pharmaceutical compositions comprising said peptide ligands and to the use of said peptide ligands in preventing, suppressing or treating a disease or disorder characterised by overexpression of EphA2 in diseased tissue (such as a tumour).Type: ApplicationFiled: July 30, 2020Publication date: August 18, 2022Applicants: BicycleTx Limited, BicycleTx LimitedInventors: Punit UPADHYAYA, Johanna LAHDENRANTA, Gemma MUDD, Kevin MCDONNELL
-
Patent number: 11396530Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.Type: GrantFiled: October 28, 2020Date of Patent: July 26, 2022Assignee: BICYCLETX LIMITEDInventors: Paul Beswick, Gemma Elizabeth Mudd, Kevin McDonnell, Gabriela Ivanova-Berndt, Katerine Van Rietschoten, David Witty, Michael Skynner
-
Patent number: 11332500Abstract: The present invention relates to heterotandem bicyclic peptide complexes which comprise a first peptide ligand, which binds to a component present on a cancer cell, conjugated via a linker to a second peptide ligand, which binds to a component present on an immune cell. The invention also relates to the use of said heterotandem bicyclic peptide complexes in preventing, suppressing or treating cancer.Type: GrantFiled: October 5, 2020Date of Patent: May 17, 2022Assignee: BICYCLETX LIMITEDInventors: Gemma Mudd, Punit Upadhyaya, Kevin McDonnell
-
Patent number: 11312749Abstract: The present invention relates to a heterotandem bicyclic peptide complex which comprises a first peptide ligand, which binds to EphA2, conjugated via a linker to two second peptide ligands, which bind to CD137. The invention also relates to the use of said heterotandem bicyclic peptide complex in preventing, suppressing or treating cancer.Type: GrantFiled: July 29, 2020Date of Patent: April 26, 2022Assignee: BicycleTx LimitedInventors: Gemma Mudd, Punit Upadhyaya, Kevin McDonnell, Johanna Lahdenranta
-
Patent number: 11306123Abstract: The present invention relates to a heterotandem bicyclic peptide complex which comprises a first peptide ligand, which binds to Nectin-4, conjugated via a linker to two second peptide ligands, which bind to CD137. The invention also relates to the use of said heterotandem bicyclic peptide complex in preventing, suppressing or treating cancer.Type: GrantFiled: July 29, 2020Date of Patent: April 19, 2022Assignee: BICYCLETX LIMITEDInventors: Gemma Mudd, Punit Upadhyaya, Kevin McDonnell, Johanna Lahdenranta
-
Patent number: 11261214Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of CD137. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD137.Type: GrantFiled: August 3, 2018Date of Patent: March 1, 2022Assignee: BicycleTx LimitedInventors: Liuhong Chen, Rachid Lani, Kevin McDonnell, Gemma Mudd, Peter Park
-
Patent number: 11241473Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.Type: GrantFiled: September 2, 2020Date of Patent: February 8, 2022Assignee: BicycleTx LimitedInventors: Paul John Beswick, Gabriela Ivanova-Berndt, Gemma Elizabeth Mudd, Silvia Pavan, Michael Skynner, Daniel Paul Teufel, Katerine Van Rietschoten